Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Trane Technologies (TT), a climate innovator, announced Monday its agreement to acquire Farrar Scientific, a provider of ultra-low temperature control for biopharmaceutical and other life science applications.


RTTNews | Sep 13, 2021 07:30AM EDT

07:30 Monday, September 13, 2021 (RTTNews.com) - Trane Technologies (TT), a climate innovator, announced Monday its agreement to acquire Farrar Scientific, a provider of ultra-low temperature control for biopharmaceutical and other life science applications.

The upfront transaction value is $250 million, with a total transaction value of up to $365 million. This includes $115 million in additional payout potential in 2025 tied to the attainment of key financial targets.

The transaction includes Farrar Scientific's assets, including its patented ultra-low temperature control technologies, a development and assembly operation in Marietta, Ohio, and its specialized team of employees.

The acquisition is expected to be modestly accretive to earnings per share in the first three years. The transaction is expected to close in the fourth quarter of 2021, subject to regulatory approval and customary closing conditions.

The company expects to fund the deal with available cash on hand.

Trane has appointed Holly Paeper, current vice president of Strategic Sales, Commercial HVAC Americas, as president of the new business, Trane Technologies Life Science Solutions. The new unit will operate as part of the company's Commercial HVAC Americas business unit.

Following the acquisition, Farrar Scientific founder and chief technology officer Scott Farrar will serve as vice president of technology and innovation in Trane Technologies' Life Science Solutions, and Jim Vuksic, Farrar Scientific's president and CEO, will serve as an advisor to the team.

Dave Regnery, CEO of Trane Technologies, said, "Farrar Scientific has revolutionized ultra-low temperature control for biopharmaceutical companies and become a critical supplier to large pharma customers. It brings technologies that meet critical needs in the addressable healthcare manufacturing and bioprocessing market, which is expected to grow to $1.65 billion by 2023."

Read the original article on RTTNews ( https://www.rttnews.com/3225118/trane-technologies-to-buy-farrar-scientific-for-up-to-365-mln-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC